H. Pai

发表

Evaluation of dosimetric parameters and disease response after 125 iodine transperineal brachytherapy for low- and intermediate-risk prostate cancer.

W. J. Morris, I. Spadinger, M. Keyes, 2009, International journal of radiation oncology, biology, physics.

Rectal toxicity and rectal dosimetry in low-dose-rate (125)I permanent prostate implants: a long-term study in 1006 patients.

Howard Pai, Ingrid Spadinger, Ross Halperin, 2012, Brachytherapy.

Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer.

W. J. Morris, I. Spadinger, M. Keyes, 2009, Urology.

Patient Accessible Electronic Health Records: Exploring Recommendations for Successful Implementation Strategies

G. Eysenbach, K. Leonard, H. Pai, 2008, Journal of medical Internet research.

Population‐based 10‐year oncologic outcomes after low‐dose‐rate brachytherapy for low‐risk and intermediate‐risk prostate cancer

Howard Pai, Ingrid Spadinger, Scott Tyldesley, 2013, Cancer.

M. Brundage, T. Panzarella, H. Pai, 2019, Journal of medical Internet research.

Standard Treatments Induce Antigen-Specific Immune Responses in Prostate Cancer

B. Nelson, P. Rennie, H. Pai, 2007, Clinical Cancer Research.

Urinary incontinence in prostate cancer patients treated with external beam radiotherapy.

M. Keyes, S. Tyldesley, M. McKenzie, 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Endoscopic response predicts for survival and organ preservation after primary chemoradiotherapy for esophageal cancer.

E. Berthelet, H. Pai, I. Olivotto, 2003, International journal of radiation oncology, biology, physics.

Implementation of osteoporosis screening guidelines in prostate cancer patients on androgen ablation.

G. Duncan, H. Pai, D. Kendler, 2009, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Isolated vaginal recurrences in endometrial carcinoma: treatment results using high-dose-rate intracavitary brachytherapy and external beam radiotherapy.

B. Clark, H. Pai, L. Souhami, 1997, Gynecologic oncology.

Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial.

J. Crook, H. Pai, P. Truong, 2010, International journal of radiation oncology, biology, physics.

Low-Dose-Rate Brachytherapy Is Superior to Dose-Escalated EBRT for Unfavourable Risk Prostate Cancer: The Results of the ASCENDE-RT* Randomized Control Trial

W. J. Morris, M. Keyes, G. Duncan, 2015 .

Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial

A. Louie, D. Palma, S. Gaede, 2020, BMC Cancer.

Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5

A. Mestrovic, N. Chng, S. Tyldesley, 2018, BMC Cancer.

Pain response in a population-based study of radium-223 (Ra223) for metastatic castration-resistant prostate cancer.

G. Duncan, S. Tyldesley, V. Lapointe, 2018, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.

W. J. Morris, M. Keyes, G. Duncan, 2017, International journal of radiation oncology, biology, physics.

Randomized study evaluating testosterone recovery using short-versus long-acting luteinizing hormone releasing hormone agonists.

M. Keyes, T. Pickles, E. Berthelet, 2011, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Effects of Standard Treatments on the Immune Response to Prostate Cancer

B. Nelson, H. Pai, C. Ludgate, 2008 .

Hemoglobin levels do not predict biochemical outcome for localized prostate cancer treated with neoadjuvant androgen-suppression therapy and external-beam radiotherapy.

G. Duncan, S. Tyldesley, A. Agranovich, 2006, International journal of radiation oncology, biology, physics.

Neoadjuvant hormone therapy and external-beam radiation for localized high-risk prostate cancer: the importance of PSA nadir before radiation.

E. Berthelet, H. Pai, P. Blood, 2005, International journal of radiation oncology, biology, physics.

141 Acute and Late Urinary Toxicity in 606 Prostate Brachytherapy Patients

M. Keyes, V. Moravan, T. Pickles, 2006 .

Tumor-associated autoantibodies correlate with poor outcome in prostate cancer patients treated with androgen deprivation and external beam radiation therapy

B. Nelson, H. Pai, J. Lum, 2014, Oncoimmunology.

Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cance

W. J. Morris, G. Duncan, S. Tyldesley, 2017, International journal of radiation oncology, biology, physics.

Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial.

A. Mestrovic, N. Chng, S. Tyldesley, 2022, JAMA oncology.

Hypothalamic/pituitary function following high-dose conformal radiotherapy to the base of skull: demonstration of a dose-effect relationship using dose-volume histogram analysis.

D. Finkelstein, B. Fullerton, J. Loeffler, 2001, International journal of radiation oncology, biology, physics.

Castration induces autoantibody and T cell responses that correlate with inferior outcomes in an androgen‐dependent murine tumor model

B. Nelson, P. Rennie, H. Pai, 2009, International journal of cancer.

Rectal Ulcers and Rectoprostatic Fistulas after (125)I Low Dose Rate Prostate Brachytherapy.

W. J. Morris, M. Keyes, S. Tyldesley, 2016, The Journal of urology.

Overexpression of p53 protein does not predict local-regional control or survival in patients with early-stage squamous cell carcinoma of the glottic larynx treated with radiotherapy.

H. Pai, G. Shenouda, M. Black, 1998, International journal of radiation oncology, biology, physics.

ASCENDE-RT*: A multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer.

W. J. Morris, G. Duncan, S. Tyldesley, 2015 .

Toxicity after (125)I prostate brachytherapy in patients with inflammatory bowel disease.

W. J. Morris, M. Keyes, H. Pai, 2013, Brachytherapy.

Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial

A. Louie, D. Palma, S. Gaede, 2020, BMC Cancer.

Maximizing rectal dose sparing with hydrogel: A retrospective planning study

I. Gagne, H. Pai, A. Alexander, 2019, Journal of applied clinical medical physics.

An Updated Analysis of the Survival Endpoints of ASCENDE-RT.

W. J. Morris, M. Keyes, G. Duncan, 2022, International journal of radiation oncology, biology, physics.

Meeting the health information needs of prostate cancer patients using personal health records.

F. Lau, H. Pai, J. Barnett, 2013, Current oncology.

Long‐Term Prostate Specific Antigen Stability and Predictive Factors of Failure after Permanent Seed Prostate Brachytherapy

M. Keyes, J. Crook, M. McKenzie, 2018, The Journal of urology.

Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients.

Howard Pai, Ingrid Spadinger, Stacy Miller, 2009, International journal of radiation oncology, biology, physics.

Penile necrosis requiring penectomy complicating recto-urethral fistula post prostate cancer external beam radiation and brachytherapy.

H. Pai, J. Gray, Alexandar Mihailovic, 2014, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Late urinary side effects 10 years after low-dose-rate prostate brachytherapy: population-based results from a multiphysician practice treating with a standardized protocol and uniform dosimetric goals.

W. J. Morris, I. Spadinger, M. Keyes, 2014, International journal of radiation oncology, biology, physics.

Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapy.

M. Keyes, G. Duncan, S. Tyldesley, 2004, International journal of radiation oncology, biology, physics.

Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? A secondary analysis of the population-based phase II SABR-5 trial.

A. Mestrovic, N. Chng, S. Tyldesley, 2023, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5

A. Mestrovic, N. Chng, S. Tyldesley, 2018, BMC Cancer.

Is Canada ready for patient accessible electronic health records? A national scan

Howard Pai, Gunther Eysenbach, David Wiljer, 2008, BMC Medical Informatics Decis. Mak..

Radiation oncology and medical physicists quality assurance in British Columbia Cancer Agency Provincial Prostate Brachytherapy Program.

Howard Pai, William James Morris, Ingrid Spadinger, 2013, Brachytherapy.

Prospective evaluation of the prevalence and severity of fatigue in patients with prostate cancer undergoing radical external beam radiotherapy and neoadjuvant hormone therapy.

E. Berthelet, H. Pai, P. Truong, 2006, The Canadian journal of urology.

Nasopharyngeal Castleman's disease.

M. Tsai, H. Pai, P. Yen, 1996, Journal of the Formosan Medical Association = Taiwan yi zhi.

Standard Treatments Induce Antigen-Specific Immune Responses in Prostate Cancer

B. Nelson, P. Rennie, H. Pai, 2007, Clinical Cancer Research.

M. Brundage, T. Panzarella, H. Pai, 2019, Journal of medical Internet research.

Web-based electronic health information systems for prostate cancer patients.

Francis Lau, H. Pai, Howard H Pai, 2005, The Canadian journal of urology.

Impact of neoadjuvant androgen ablation and other factors on late toxicity following external beam prostate radiation

M. Keyes, G. Duncan, S. Tyldesley, 2002 .

Bmc Medical Informatics and Decision Making Is Canada Ready for Patient Accessible Electronic Health Records? a National Scan

G. Eysenbach, K. Leonard, H. Pai, 2008 .